Castle Biosciences Plans acquisition of Cernostics for up to $80M; Acquisition Closes
Castle Biosciences, Inc. signed a definitive agreement to acquire privately held precision diagnostics firm Cernostics, Inc. (specializes in spatial biology and artificial intelligence (AI)-driven image analysis of tissue biopsies), an Illumina Ventures company. The transaction is expected to close prior to year-end 2021.
- In Vitro Diagnostics
Diagnostic Imaging Equipment & Supplies
- Molecular Imaging
- Diagnostic Imaging Equipment & Supplies
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Artificial Intelligence
- Full Acquisition
- Includes Contract
- Includes Earnout
- Payment Includes Cash for Equity
- Payment Includes Stock
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.